Systemic lupus erythematosus treatment regimens during 2010
| Russia (n=196) | Kazakhstan (n=109) | Ukraine (n=92) | |
|---|---|---|---|
| Oral glucocorticoids | 192 (98.0%) | 108 (99.1%) | 89 (96.7%) |
| Daily dose of methylprednisolone mg/day (mean 2010 dose) | 17.1 (11.9) | 35.0 (7.1) | 12.4 (10.2) |
| Daily dose of prednisolone mg/day (mean 2010 dose) | 16.6 (12.0) | 21.0 (13.7) | 19.2 (12.8) |
| Antimalarial drugs | 80 (40.8%) | 20 (18.3%) | 35 (38.0%) |
| Immunosuppressants/cytotoxic | 92 (46.9%) | 58 (53.2%) | 19 (20.7%) |
| NSAIDs | 15 (7.7%) | 66 (60.6%) | 49 (53.3%) |
| Biological therapy | 25 (12.8%) | 2 (1.8%) | 0 (0.0%) |
| Drugs for osteoporosis | 95 (48.5%) | 25 (22.9%) | 18 (19.6%) |
Percentages were calculated from the valid data. Doses are presented as mean value (SD).
Immunosuppressants/cytotoxic drugs included azathioprine, chlorambucil, ciclosporin, cyclophosphamide, methotrexate and mycophenolate mofetil.
NSAIDs, non-steroidal anti-inflammatory drugs.